Simvastatin enhances radiation sensitivity of colorectal cancer cells
- 152 Downloads
Neoadjuvant chemoradiation (CRT) for rectal cancer induces variable responses, and better response has been associated with improved oncologic outcomes. Our group has previously shown that the administration of HMG-CoA reductase inhibitors, commonly known as statins, is associated with improved response to neoadjuvant CRT in rectal cancer patients. The purpose of this study was to study the effects of simvastatin on colorectal cancer cells and explore its potential as a radiation-sensitizer in vitro.
Four colorectal cancer cell lines (SW480, DLD1, SW837, and HRT18) were used to test the effects of simvastatin alone, radiation alone, and combination therapy. Outcome measures included ATP-based cell viability, colony formation, and protein (immunoblot) assays.
The combination of radiation and simvastatin inhibited colony formation and cell viability of all four CRC lines, to a greater degree than either treatment alone (p < 0.01). In addition, the effects of simvastatin in this combination therapy were dose dependent, with increased concentrations resulting in more potentiated inhibitory effects. The radiosensitizing effects of simvastatin on cell viability were negated by the presence of exogenous GGPP in the media. On protein analyses of irradiated cells, simvastatin treatment inhibited phosphorylation of ERK1/2, in a dose-dependent manner, while the total levels of ERK1/2 remained stable. In addition, the combined treatment resulted in increased levels of cleaved caspase 3, indicating greater apoptotic activity in the cells treated with radiation and simvastatin together.
Treatment with simvastatin hindered CRC cell viability and enhanced radiation sensitivity in vitro. These effects were tied to the depletion of GGPP and the decreased phosphorylation of ERK1/2, suggesting a prominent role for the EGFR-RAS-ERK1/2 pathway, through which statin enhances radiation sensitivity.
KeywordsColorectal cancer Radiation Sensitivity Response Statins
Georgios Karagkounis is the recipient of the 2015 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Career Development Award (CDA) and the American Society of Colon and Rectal Surgeons (ASCRS) General Surgery Resident Research Initiation Grant #25. Matthew F. Kalady is the Krause-Lieberman Chair in Colorectal Surgery.
This study was funded in part by the 2015 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Career Development Award and the American Society of Colon and Rectal Surgeons (ASCRS) General Surgery Resident Research Initiation Grant #25 to Georgios Karagkounis.
Compliance with ethical standards
Georgios Karagkounis, Jennifer DeVecchio, Sylvain Ferrandon, and Matthew F. Kalady have no conflicts of interest or financial ties to disclose.
- 1.O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331(8):502–507. doi: 10.1056/nejm199408253310803 CrossRefPubMedGoogle Scholar
- 2.Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638–646. doi: 10.1056/NEJMoa010580 CrossRefPubMedGoogle Scholar
- 3.Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. doi: 10.1056/NEJMoa040694 CrossRefPubMedGoogle Scholar
- 4.Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933. doi: 10.1200/jco.2011.40.1836 CrossRefPubMedGoogle Scholar
- 5.Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688–8696. doi: 10.1200/jco.2005.02.1329 CrossRefPubMedGoogle Scholar
- 6.Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suarez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9):835–844. doi: 10.1016/s1470-2045(10)70172-8 CrossRefPubMedGoogle Scholar
- 16.Lee SJ, Lee I, Lee J, Park C, Kang WK (2014) Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancer. Br J Cancer 111(3):497–505. doi: 10.1038/bjc.2014.283 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK (2014) Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs 32(3):535–541. doi: 10.1007/s10637-014-0065-x CrossRefPubMedGoogle Scholar
- 19.Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW, Peppelenbosch MP, van den Brink GR, Hardwick JC (2011) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell ‘stemness’ via the bone morphogenetic protein pathway. Gut 60(11):1544–1553. doi: 10.1136/gut.2011.237495 CrossRefPubMedGoogle Scholar
- 20.Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobagyi GN, Buchholz TA, Ueno NT, Woodward WA (2014) Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3(7):849–856. doi: 10.5966/sctm.2013-0204 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Sanli T, Liu C, Rashid A, Hopmans SN, Tsiani E, Schultz C, Farrell T, Singh G, Wright J, Tsakiridis T (2011) Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 6(3):439–450. doi: 10.1097/JTO.0b013e3182049d8b CrossRefPubMedGoogle Scholar
- 22.Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45(7):895–903CrossRefPubMedGoogle Scholar